Searched for
LANTUS SALES DECLINE
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhat is evident in the last few trading sessions is how the street is treating Q4 earnings numbers. If a company delivers in terms of numbe...- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhen markets come under the kind of pressure they are experiencing these days, the bears don't see fundamentals; it is all about selling. A...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsThe Indian markets on Wednesday rose in lockstep with global peers that reacted, among other things, to the possibility of an end to the Ru...
- These mid-cap stocks with ‘strong buy’ & ‘buy’ recos can rally over 30%, according to analystsGeopolitical tensions were the top concern of the markets in the past couple of weeks. The way things have panned out so far, it would appe...
- Sweet Surrender: Sanofi puts star insulin brand Lantus up for sale, eyes Rs 2,000 cr from Indian pharma giantsSanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licens...
- For investors with patience to digest a short-term decline. 7 mid-cap stocks with upside potential of up to 53%The street is grappling with its own fears and anxieties. Will the correction in the mid-caps continue for longer? And the bigger question:...
- Forget additional 2.5% LTCG, finally it is economy and earnings: 4 midcap stocks from different sectors with an upside potential of up to 37%The reaction of the street to the increase in both short and long capital gains tax is stronger because it was not expected by any section ...
- Indian companies have made a comeback. Will MNCs be able to do it ? 7 MNC pharma stocks with upside potential of up to 21%While they still trade at premium valuations, they have not created wealth for shareholders. The fact is an age-old theory that just having...
- Own midcaps? Do a check & balance exercise to avoid decision of haste: 7 midcaps from different sectors with an upside potential of upto 49%Every now and then the market goes through phases, where it prefers a certain set of stocks, not based on sector but based on the overall m...
- Stocks to buy: Will pharma scrips keep rising? 3 stocks with potential upside of up to 30.6%In the December 2023 quarter, the pharma stock universe (89 stocks) reported 12% and 27% y-o-y growth in revenue and PAT, respectively. Com...
- Will the wave of restructuring help? 7 MNC pharma stocks with upside potential of up to 14%In the last three years, Novartis is the third MNC pharma company which has announced sale of a part of its business in India. Some of thes...
- Pharma Industry staring at 30-40 bps hit on updated NLEMManchanda added that the anti-infectives treating HIV, TB and drug cessation treatments in the list doesn't have a major impact on margins ...
- Sanofi's valuations are attractive: Why it is stock pick of weekSanofi India’s management has adopted cost control measures and has lowered promotional spends, which was visible in 2020. Its digital push...
- Pharma retail market shrinks 12% in April, worst in 3 yearsDomestic pharma retail market saw growth declining by 12% in April, sharpest falls in three years.
- Sanofi bets on India with portfolio of drugs for diabetes, rare diseasesSanofi reported one of the sharpest falls in its global sales in the fourth quarter, owing to the decline in diabetes drug sales, a controv...
- Sanofi India stock likely to be re-rated on company's improving fundamentalsHowever, unlike other multinational pharmaceutical companies, Sanofi India was not analysts’ favourite for quite some time.
- Sanofi-Aventis scans India for acquisitionsSanofi-Aventis which bought companies in Brazil, Mexico, and the home-grown Shanta Biotech this year, has sent a delegation to India to fin...
- Plavix copies hit Sanofi-Aventis, net drops 12%Sanofi-aventis reported a 12% drop in third-quarter profit on Tuesday, citing the loss of top-selling blood thinner Plavix to generic compe...
Load More
